Latest Breaking News On - Centrexion therapeutics corp - Page 1 : comparemela.com

Clough Global Dividend and Income Fund : Annual Report at 2023-10-31 -December 28, 2023 at 09:10 am EST

CLOUGH GLOBAL DIVIDEND AND INCOME FUND CLOUGH GLOBAL EQUITY FUND CLOUGH GLOBAL OPPORTUNITIES FUND Annual Report .

Non-Opioid Pain Treatment Market to Notice Utmost Growth of USD 807.32 Million By 2029

Data Bridge Market Research conducted a recent market intelligence study, thoroughly analysing the Non-Opioid Pain Treatment Market. The newly published report employs an appealing layout that presents essential data using visually engaging tables, graphs, charts, and figures.The Non-Opioid Pain Treatment market res.

GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum

GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30. The SACHS NIF, which is entirely virtual, will include a SPOTLIGHT SHOWCASE session describing GB Sciences recent pivot and novel drug development pipeline. In addition, Dr. Andrea Small-Howard, the Chief Science Officer and Director of GB Sciences, is an invited speaker on the Pain, Migraines, and Addiction Panel during a live session on Therapeutics Day 2, April 29 at 11:50 a.m. EDT.

GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum

Osteoarthritis Pain Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Product Development Milestones - ResearchAndMarkets.com